Bone Sonometry PMAs Need Supporting Data From Caucasian Females
This article was originally published in The Gray Sheet
Executive Summary
Patient databases used in support of premarket approval of bone densitometry/sonometry devices in assessing fracture risk should consist of Caucasian females 20-29, according to an FDA final guidance.
You may also be interested in...
Race/Gender-Specific Densitometry Database Warning Endorsed By Panel
Gender and ethnicity-specific databases used with bone densitometry/sonometry devices to assess fracture risk should include cautionary language that their relevance has not undergone sufficient clinical evaluation, FDA's Radiological Devices Panel agreed at a May 17 meeting in Rockville, Maryland.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.